Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on February 5, 2026, to announce its financial results for the fourth quarter and full year of 2025. The filing includes a press release (Exhibit 99.1) detailing these results and a presentation (Exhibit 99.2) covering financial and operating initiatives. Investors should refer to these documents, available on the company's website, for a comprehensive understanding of BMY's recent performance and strategic direction. Both the press release and presentation reference non-GAAP financial information. The company emphasizes that reconciliations between non-GAAP and GAAP measures, along with explanations for the use of non-GAAP figures, are provided within the press release. Investors are advised to review these reconciliations carefully when evaluating the company's financial health and operational efficiency.
Key Highlights
- 1BMY announced its Q4 2025 and full-year 2025 financial results via an earnings press release filed on February 5, 2026.
- 2A supplementary presentation on financial and operating initiatives is also available and furnished as part of this filing.
- 3Both the earnings release and presentation were made available on the company's website (www.bms.com).
- 4The company's conference call and webcast to discuss these results occurred on February 5, 2026, at 8:00 a.m. Eastern time.
- 5Key financial and operational performance data for Q4 and FY 2025 are detailed in the provided press release and presentation.
- 6Both documents contain non-GAAP financial information, with reconciliations to GAAP measures provided in the earnings press release.